(Reuters) – AstraZeneca Plc said on Friday its cancer drug Imfinzi had been approved in Europe and Britain for a spaced-out regimen in a common type of lung cancer … AstraZeneca's top-selling drug Tagrisso has been shown to slow the spread of a certain type of lung cancer to the brain when diagnosed at an early stage, the British drugmaker said on Saturday. Two AstraZeneca drugs tackling lung cancer in different ways delivered impressive clinical results on Saturday, helping the British group offset July's big clinical trial setback in the disease. Includes side effects, intera AstraZeneca says its Tagrisso drug cut by 83% the risk of disease recurrence or death in patients with forms of early-stage non-small-cell lung cancer. This page lists cancer drugs approved by the Food and Drug Administration (FDA) for lung cancer. It’s for adult patients with extensive-stage small-cell lung cancer … The list includes generic and brand names. Right now, there are no HER2-targeting drugs approved in non-small cell lung cancer, but partners AstraZeneca and Daiichi Sankyo are hoping to … AstraZeneca’s lung cancer drugs Imfinzi is AstraZeneca’s latest lung cancer drug to receive approval from the FDA. Imfinzi (durvalumab) is a cancer medicine that works with your immune system to interfere with the growth and spread of cancer cells in the body. The individual drugs in the combinations are FDA-approved. Imfinzi is used to treat non-small cell lung cancer and small cell lung cancer. A study of an AstraZeneca lung cancer treatment was recently stopped two years early because independent trial advisors concluded the drug, called Tagrisso, had already clearly shown a benefit over placebo. This page also lists common drug combinations used in lung cancer. (Reuters) - AstraZeneca's top-selling drug Tagrisso has been shown to hold back a certain type of lung cancer when diagnosed at an early stage, the British drugmaker said on Thursday, potentially adding billions to its sales potential. On Thursday, doctors get to see why. Results show Tagrisso reduced the risk of disease progression following surgery by 80%, a result the lead study investigator called a "home run." Britain's AstraZeneca Plc, the target of a $106 billion takeover effort by Pfizer Inc, released promising data on Wednesday for a new lung cancer treatment targeting a … The late-stage clinical trials indicated that the drug not only improved overall survival benefit but also improved response rates of patients suffering from small cell lung cancer, AstraZeneca …